Bindarit from MedChemExpress

Product Specs
ItemBindarit
CompanyMedChemExpress
Price $99.00Supplier Page View Company Product Page
Catalog NumberHY-B0498
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.53%
TypeChemical
Molecular Weight324.37
FormulaC₁₉H₂₀N₂O₃
Research AreaNeurological Disease; Inflammation/Immunology; Endocrinology; Cancer

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) SPARC modulates macrophage-like phenotype transformation in VSMCs and triggers a vicious cycleFront Cell Dev BiolMay 7, 2026Gengfan Ye, Hongcai Wang, Kuan Feng, Shiwei Li, Xuebin Wen, Zhenqiang Li, Wei Chen, Maosong ChenROS inhibitor acetylcysteine (Catalog# HY-B0215), aspirin (Catalog# HY-14654), and bindarit (Catalog# HY-B0498) were from the MedChemExpress, China. Cell culture and transfection VSMCs were cultured in the recommended

(2) Characterizing the SASP-Dependent Paracrine Spreading of Senescence Between Human Brain Cell TypesbioRxivFebruary 14, 2026Taylor Russo, Markus Riesslandtypes. Bindarit CM collection Treatment with the CCL2 synthesis inhibitor Bindarit (MedChemExpress, Catalog No. HY-B0498) (30) was used to specifically target CCL2 production in senescent cells. Bindarit was dissolved in

(3) Lactate‐mediated activation of GPR81 regulates BCR /Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tensionThe Journal of PathologyDecember 1, 2025Giulio Menegazzi, Dayana Desideri, Alessio Biagioni, Elisabetta Rovida, Persio Dello Sbarba, Silvia PeppicelliNo.: HY‐13966; MedChemExpress) was used at a final concentration of 1 mm. Bindarit (Catalogue No.: HY‐B0498; MedChemExpress), a MCT‐4 inhibitor, was used at 200 μm; AR‐C155858 (Catalogue No.: HY‐13248; MedChemExpress),

(4) Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8 + T cellsJournal for ImmunoTherapy of CancerNovember 24, 2025Yijiao Chen, Xudong Liu, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, et al.MC38 tumor inoculation and subsequently every 3 days. For the Bindarit treatment (5 mg/kg, Cat No. HY-B0498, MCE), Bindarit was administered by gavage every 3 days, commencing once the tumors became palpable.

(5) Excessive MYC Orchestrates Macrophages induced Chromatin Remodeling to Sustain Micropapillary‐Patterned Malignancy in Lung AdenocarcinomaAdvanced ScienceFebruary 3, 2025Xuming Song, Zehao Pan, Yi Zhang, Wenmin Yang, Te Zhang, Hui Wang, Yuzhong Chen, Xinnian Yu, Hanlin Ding, Rutao Li, et al.control (6µg mL−1, R&D Systems, RR_ID:AB_357344) or CCL7/8 inhibitor Bindarit (5µM, MedChemExpress, #HY‐B0498). Cell Transfection and Establishment of Stably Transduced Cells To track the transplanted tumor cells

(6) Monocytes serve as Shiga toxin carriers during the development of hemolytic uremic syndromeCellular & molecular biology lettersJanuary 27, 2025Sun X, Qu S, Zhou F, Shi F, Wu Y, Gu L, Liu M, Bian Z, Shi L, Liu Z, et al.antibody every day for 3 days (BioLegend, 150103) or administration with bindarit (100 mg/kg/day, MCE, HY-B0498) through gavage. Mice were monitored daily, and the tissues were collected and analyzed after being

(7) Single-Cell RNA Sequencing Analysis Reveals the Role of Macrophage-Mediated CD44-AKT-CCL2 Pathways in Renal Tubule Injury during Calcium Oxalate Crystal FormationResearch (Washington, D.C.)January 1, 2025Jin X, Jian Z, Ma Y, Wen J, Chao N, Chen X, Xiang L, Yuan Y, Liu L, Li Y, et al.were obtained for scRNA-seq (n = 6). The CCL2 antagonist group received a CCL2 antagonist [68–70] (HY-B0498, Bindarit, 50 mg/kg, MCE, Shanghai, China) combined with the intraperitoneal injection of glyoxylate.

(8) Choroid plexus CCL2‒CCR2 signaling orchestrates macrophage recruitment and cerebrospinal fluid hypersecretion in hydrocephalusActa Pharmaceutica Sinica BOctober 1, 2024Qiguang Wang, Fei Liu, Yue Li, Huan Zhang, Xin Qi, Ke Wu, Yi Zhang, Shenglan You, Wenke Liu, Xuhui Hui, et al.Jersey, USA). To inhibit the LPS indued CCL2 production in ChP epithelial cells, the Bindarit (cat: HY-B0498, MCE, New Jersey, USA) was used. 2.3 Transcriptome sequencing of ChP The rats in both shame and IVH

(9) Single-cell RNA sequencing reveals recruitment of the M2-like CCL8high macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapyJ Transl MedMarch 25, 2024Haonan Yang, Zheng Lei, Jiang He, Lu Zhang, Tangmin Lai, Liu Zhou, Nuohan Wang, Zheng Tang, Jiangdong Sui, Yongzhong Wuwere cultured for a limited number of generations. The CCL8 inhibitor Bindarit (AF2838, MCE, Cat#: HY-B0498) was diluted in 10% DMSO, then 45% PEG300 (MCE, Cat#: HY-Y0873) and 45% Saline. Recombinant CCL8 protein

(10) The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic miceCardiovascular researchDecember 1, 2009Grassia G, Maddaluno M, Guglielmotti A, Mangano G, Biondi G, Maffia P, Ialenti A.

(11) Bindarit retards renal disease and prolongs survival in murine lupus autoimmune diseaseKidney internationalMarch 1, 1998Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G.

(12) Identification of an immunologically distinct papillomavirus from lesions of epidermodysplasia verruciformisJournal of the National Cancer InstituteOctober 1, 1977Pass F, Reissig M, Shah KV, Eisinger M, Orth G.

Be the First to Write a Review!

Bindarit from MedChemExpress

Description

MedChemExpress

Citations (12)

Reviews

Bindarit from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map